Transgenomic's Q1 Sales Sag 20 Percent as R&D Grows and Loss Widens

May 11, 2007

NEW YORK (GenomeWeb News) — Transgenomic yesterday said first-quarter revenues decreased 20 percent as R&D spending rose 75 percent and its net loss ballooned by 276 percent.

Total receipts for the three months ended March 31 fell to $5.2 million from $6.5 million year over year.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Here We Are Again

American scientists find themselves once again warning the Trump administration not to dismiss science, the New Yorker report.

In the Pink

A new study suggests CRISPR could be used to save coral reefs from dying off, Forbes reports.

All Tied Up in a Bow

Researchers have found that the i-motif shape of DNA previously observed in the lab also exists in human cells, and that it may serve a purpose.

This Week in PNAS

In PNAS this week: a genomic, transcriptomic, and metabolomic analysis of the tea plant, Arabidopsis thaliana's adaptations to specific local environments, and more.

Main menu